Navigation Links
New Study Shows that PEGASYS(R) Regimen Provides Higher Sustained Virological Response Rates for Hepatitis C Patients
Date:11/1/2008

c hepatitis B (HBeAg positive and HBeAg negative chronic hepatitis B who have compensated liver disease and evidence of viral replication and liver inflammation).

PEGASYS is dosed at 180mcg as a subcutaneous injection taken once a week. COPEGUS is available as a 200mg tablet, and is administered orally two times a day as a split dose. Roche has backed PEGASYS with the most extensive clinical research program ever undertaken in hepatitis C, with major studies initiated to advance treatment for hepatitis C patients with unmet needs, including patients co-infected with HIV and HCV, African Americans, patients with cirrhosis, and patients who have failed to respond to previous therapy.

IMPORTANT SAFETY INFORMATION

PEGASYS, alone or in combination with COPEGUS, is indicated for the treatment of adults with chronic hepatitis C virus infection who have compensated liver disease and have not been previously treated with interferon alpha. Patients in whom efficacy was demonstrated included patients with compensated liver disease and histological evidence of cirrhosis (Child-Pugh class A).

Alpha interferons, including PEGASYS(R) (Peginterferon alfa-2a), may cause or aggravate fatal or life-threatening neuropsychiatric, autoimmune, ischemic, and infectious disorders. Patients should be monitored closely with periodic clinical and laboratory evaluations. Therapy should be withdrawn in patients with persistently severe or worsening signs or symptoms of these conditions. In many, but not all cases, these disorders resolve after stopping PEGASYS therapy (see CONTRAINDICATIONS, WARNINGS, PRECAUTIONS and ADVERSE REACTIONS in complete product information).

Use with Ribavirin. Ribavirin, including COPEGUS(R), may cause birth defects and/or death of the fetus. Extreme care must be taken to avoid pregnancy in female patients and in female partners of male patients. Ribavirin causes hemolytic anemia. The anemia associated with ribavirin therapy may resu
'/>"/>

SOURCE Roche
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. New International Study Shows Women With Symptomatic Fibroids Delaying Treatment Despite Substantial Burden on Quality of Life
2. Study Found That Long Term Use of Advair Diskus(R) 250/50 Did Not Adversely Affect Bone Loss in Patients with COPD
3. Recent Study Demonstrated VYVANSE(R) (lisdexamfetamine dimesylate) CII Provided Improvements in Behavior, Inattention, and Math Test Scores from 1.5 Hours up to 13 Hours following Administration in Children with ADHD
4. Grapes May Aid a Bunch of Heart Risk Factors, U-M Animal Study Finds
5. NCI Funded Clinical Trial to Study Treatment of Breast Cancer Using Cryoablation
6. Nuvo Research presents positive Phase III study results for Pennsaid at leading rheumatology conference
7. Study Results Show Epratuzumab Provided Clinically Meaningful Reduced Disease Activity in Patients With Lupus
8. Rib-X Pharmaceuticals Reports Positive Phase 2 Study Results for Next Generation Oxazolidinone at 2008 ICAAC/IDSA Joint Meeting
9. Long-Term Study Evaluates Boosted PREZISTA(R) Vs. Lopinavir/Ritonavir as Part of HIV Combination Therapy in Treatment-Naive Adults
10. New Study Demonstrated ACTEMRA(R) (tocilizumab) Inhibited Progression of Joint Damage in Rheumatoid Arthritis Patients
11. ULURU Inc. Announces the Commencement of First Clinical Study Using Altrazeal(TM) Silver
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... 15, 2014  Novation, the leading health care ... several new IT value-added reseller (VAR) national contracts ... with IT goods and services at lower costs. ... well as value-added services such as initiative assistance ... New Novation agreements were awarded to CDW Government, ...
(Date:1/15/2014)... Jan. 15, 2014 Massachusetts General Hospital ... AMGN ) announced today that they have ... validate new therapeutic targets and develop novel therapies ... that affects millions worldwide. The MGH-Broad-Amgen collaboration brings ... biology, human genetics, genomic technology, and drug discovery ...
(Date:1/15/2014)... , Jan. 15, 2014  Humberto C. Antunes,  ... Achievement Award" from the Journal of Drugs in ... & Clinical Conference (ODAC). The event is January 17-20, 2014, at ... Florida . The ODAC is ... the practice of dermatology for clinical and aesthetic dermatology ...
Breaking Medicine Technology:New Novation Information Technology VAR Contracts Offer Significant Savings to Hospitals 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 2Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 3Galderma's global leader honored with a "Lifetime in Dermatology Achievement Award" by Journal of Drugs in Dermatology 4
... , NUTLEY, N.J. , April 22 ... named Head of the Oncology Discovery and Translational Area (DTA) (1), effective ... and as part of the Pharma Research and Early Development (pRED) organization, ... field of Oncology. , , ...
... April 22 /PRNewswire-Asia-FirstCall/ -- Lotus Pharmaceuticals,Inc. (OTC Bulletin Board: LTUS) ("Lotus" or the ... of China (the "PRC"), today reported it will exhibit at the 63rd,PHARMCHINA. , ... April 24-26, 2010, Venue: ... Area, , , , ...
Cached Medicine Technology:Mike Burgess Named Head of Oncology Discovery Translational Area for Roche's Pharma Research and Early Development (pRED) Organization 2Mike Burgess Named Head of Oncology Discovery Translational Area for Roche's Pharma Research and Early Development (pRED) Organization 3Lotus Pharmaceuticals to Exhibit at the 63rd PHARMCHINA 2
(Date:4/14/2014)... orphaned by HIV/AIDS in South Africa may provide insight ... behavior issues in other areas of the world, which ... that could lead to successful interventions. , A ... United Nations mentions that due to the HIV/AIDS pandemic, ... African, children are at an increased risk for mental ...
(Date:4/14/2014)... A new study shows that moderate to severe ... risk of stroke, cancer and death. , Results of ... to severe obstructive sleep apnea were four times more ... times more likely to have a stroke (HR = ... (HR = 3.4), and 2.5 times more likely to ...
(Date:4/14/2014)... Dallas study involving serious youth offenders, the answer to one ... seven years: "How long do you think you,ll live?", According ... offending over time., Author Dr. Alex Piquero said the study ... of them offend at very high rates and commit more ... much later in life offend much less., "In a lot ...
(Date:4/14/2014)... with symptoms increasing dramatically during some of the most important ... has found. , Depressive symptoms increased on average by 68 ... young men, who were around 25 years old when they ... their children. The results of the study were published April ... is the first to identify when young fathers are at ...
(Date:4/14/2014)... Lower weight babies and babies who aren,t breastfed ... risk of developing chronic inflammation and related health ... study. , "There were good reasons to hypothesize ... inflammation in adulthood," says Thomas McDade (Northwestern University), ... in the Child & Brain Development program. "It ...
Breaking Medicine News(10 mins):Health News:Researchers identify children with emotional behavior difficulties 2Health News:Researchers identify children with emotional behavior difficulties 3Health News:Study links severe sleep apnea to increased risk of stroke, cancer and death 2Health News:UT Dallas study: Youth who fail to envision future commit more crimes 2Health News:Young dads at high risk of depression, too 2Health News:Low birth weight, less breastfeeding create later health risks 2
... and P4 have clear and distinct effects on inflammatory ... infection. Recently, Ohtani et al., have shown a protective ... Other studies have demonstrated that E2 and P4 have ... been reported in human, mouse and rat stomach. However, ...
... Allergy Testing in Improving Asthma ... ... Health announced today,that it has entered a co-promotion agreement with Phadia, ... in the diagnosis,and treatment of asthma and other respiratory diseases. Under ...
... Oct. 31 In the final 72-hours of,this ... volunteers,across the country are joining 4,000 SEIU members, ... the job to bring home victory for,Barack Obama, ... working,families need., SEIU,s major GOTV operations are ...
... an exaggerated intestinal immune response to otherwise innocuous ... plays a key role in the pathophysiology of ... yet emerged. Vitamin E is a major lipophilic ... which protects membrane lipids from peroxidation by scavenging ...
... to sign up online at http://www.diabetesatlanta.org , ATLANTA, ... than 600,000 Georgians, could be present in more than,300,000 more, ... disease?, No. The answer is diabetes., And, new ... the U.S. has,nearly doubled in the past 10 years - ...
... Array of Colors and,Custom Products Giving Confident Wearers ... PISCATAWAY, N.J., Oct. 31 Siemens Hearing,Instruments, Inc., ... States, continues their commitment to personalizing solutions for,those ... hearing instruments,were announced at this year,s International Congress ...
Cached Medicine News:Health News:Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils 2Health News:Estrogen and progesterone receptor isoforms expression in the stomach of Mongolian gerbils 3Health News:Nation's #1 Respiratory Hospital Enters Agreement to Co-Promote IgE Blood Testing 2Health News:In Final 72-Hour Push, SEIU Members Get Out The Vote for Barack Obama and Other Working Family Candidates Across the Country 2Health News:Can rectal vitamin E induce remission in patients with mild to moderate ulcerative colitis? 2Health News:As Diabetes Reaches Epidemic Levels in Georgia and U.S., Thousands Drawn to Diabetes University in Atlanta Nov. 8 2Health News:Siemens Launches Motion(TM), a Complete Product Portfolio for Mild Through Severe Hearing Loss 2Health News:Siemens Launches Motion(TM), a Complete Product Portfolio for Mild Through Severe Hearing Loss 3Health News:Siemens Launches Motion(TM), a Complete Product Portfolio for Mild Through Severe Hearing Loss 4
... configured specifically for pharmaceutical powder packaging, ... are precision-joined to create ultra-smooth surfaces ... and disinfect. One-inch radius corners simplify ... strong, rigid surface without external bracing. ...
... for biological safety labs (BSL) and ... Class 10/ISO 3) and easy sterilization. ... surfaces that are easy to wipe ... simplify cleaning. Unique double-wall panel design ...
... ideal modular cleanroom for biological safety ... require cleanliness (to Class 10/ISO 3) ... to create ultra-smooth surfaces that are ... One-inch radius corners simplify cleaning. Unique ...
Inquire...
Medicine Products: